Andrew Guggenhime, PRESIDENT AND CFO at Vaxcyte, Inc. (PCVX), sold 13,500 shares at $80.12 ($1.1M) on 2024-07-18, disclosed to the SEC on 2024-07-22.
Scheduled sale ($1.1M) by PRESIDENT AND CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $80.12 | 3,095 | $248K | 22.6% |
| 2 | $80.12 | 3,095 | $248K | 22.6% |
| 3 | $81.06 | 2,500 | $203K | 18.5% |
| 4 | $82.32 | 1,479 | $122K | 11.1% |
| 5 | $82.32 | 1,479 | $122K | 11.1% |
| 6 | $83.14 | 926 |
| $77K |
| 7.0% |
| 7 | $83.14 | 926 | $77K | 7.0% |
| Total | $81.19 avg | 13,500 | $1.1M | 100% |
| Filing → |
| PCVX | SELL | 2026-06-18 | $530K | — | Filing → |
| PCVX | SELL | 2025-02-19 | $1.3M | — | Filing → |
| PCVX | SELL | 2025-01-22 | $1.4M | — | Filing → |